SEELQSeelos Therapeutics, Inc.

About Seelos Therapeutics, Inc. (SEELQ)

Seelos Therapeutics, Inc. (SEELQ) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the Expert Market tier.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012.

Products and services

we are a clinical-stage biopharmaceutical company.

SEELQ key facts

Ticker symbol

SEELQ

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

US

Year of incorporation

1987

Employees

8

Estimated market cap

$681.44 (as of Apr 11, 2025)

Shares outstanding

1,362,879

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Nov 15, 2024)

Seelos Therapeutics, Inc. leadership

• Raj Mehra — CEO
• Michael Joseph Golembiewski — CFO

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with S